Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eleven ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $25.67.

A number of research analysts recently issued reports on the stock. Wells Fargo & Company decreased their target price on shares of Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Barclays decreased their price objective on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a research report on Wednesday, April 23rd. Bank of America decreased their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. Morgan Stanley decreased their price objective on shares of Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Finally, HC Wainwright upgraded shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $18.00 to $24.00 in a research report on Wednesday, February 26th.

Arcus Biosciences Stock Performance

NYSE RCUS traded up $0.28 on Thursday, reaching $9.21. 1,482,429 shares of the company's stock traded hands, compared to its average volume of 862,284. The firm has a market cap of $974.67 million, a price-to-earnings ratio of -2.92 and a beta of 0.88. The stock has a 50 day moving average price of $8.27 and a 200-day moving average price of $11.53. Arcus Biosciences has a fifty-two week low of $6.50 and a fifty-two week high of $18.98. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.12). The business had revenue of $28.00 million for the quarter, compared to analyst estimates of $38.61 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The company's revenue for the quarter was down 80.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.05) earnings per share. Equities research analysts predict that Arcus Biosciences will post -3.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of RCUS. R Squared Ltd acquired a new position in shares of Arcus Biosciences during the 4th quarter worth about $26,000. Strs Ohio acquired a new position in shares of Arcus Biosciences during the 1st quarter worth about $67,000. E Fund Management Co. Ltd. acquired a new position in shares of Arcus Biosciences during the 1st quarter worth about $82,000. Lazard Asset Management LLC raised its position in shares of Arcus Biosciences by 3,321.3% during the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company's stock worth $93,000 after purchasing an additional 6,078 shares during the last quarter. Finally, Knott David M Jr purchased a new stake in Arcus Biosciences during the 1st quarter valued at about $94,000. Institutional investors and hedge funds own 92.89% of the company's stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.